Tenaya Therapeutics appoints Amy Burroughs to board; Eli Casdin resigns

Tenaya Therapeutics, Inc.

Eli Casdin resigned from board and audit committee effective Dec 5, 2022; no disagreement with company.
Amy Burroughs appointed Class II director, term expiring at 2023 annual meeting.
Burroughs receives annual cash retainer of $35,000 plus $7,500 for audit committee; granted option for 40,000 shares vesting monthly over 3 years.
Burroughs is President & CEO of Cleave Therapeutics, brings >20 years healthcare/biotech experience.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Eli Casdin

Director

TNYA · Tenaya Therapeutics, Inc.

Effective: 2022-12-05
Filed: December 7, 2022, 6:59 PM ET

On December 5, 2022, Eli Casdin submitted his resignation as a director of Tenaya Therapeutics, Inc. (the “Company”) and as a member of the Company’s Audit Committee (the “Audit Committee”).

Appointed

Amy Burroughs

Class II Director

TNYA · Tenaya Therapeutics, Inc.

Effective: 2022-12-05
Filed: December 7, 2022, 6:59 PM ET

On December 5, 2022, the Board appointed Amy Burroughs, to serve as a Class II director, with a term expiring at the Company’s 2023 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Eli Casdin resigned as Director at Tenaya Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On December 5, 2022, Eli Casdin submitted his resignation as a director of Tenaya Therapeutics, Inc. (the “Company”) and as a member of the Company’s Audit Committee (the “Audit Committee”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Amy Burroughs was appointed as Class II Director at Tenaya Therapeutics, Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

On December 5, 2022, the Board appointed Amy Burroughs, to serve as a Class II director, with a term expiring at the Company’s 2023 annual meeting of stockholders.

View on SEC.gov

Tenaya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-026162

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.